Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

被引：62

作者：

Chamian, Francesca ^{[1
]}

Lin, Shao-Lee ^{[1
]}

Lee, Edmund ^{[1
]}

Kikuchi, Toyoko ^{[1
]}

Gilleaudeau, Patricia ^{[1
]}

Sullivan-Whalen, Mary ^{[1
]}

Cardinale, Irma ^{[1
]}

Khatcherian, Artemis ^{[1
]}

Novitskaya, Inna ^{[1
]}

Wittkowski, Knut M. ^{[1
]}

Krueger, James G. ^{[1
]}

Lowes, Michelle A. ^{[1
]}

机构：

[1] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2007年 / 5卷 / 1期

关键词：

D O I：

10.1186/1479-5876-5-27

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease. Methods: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis. Results: In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7(-) CD45RA(-)) ( mean 63% reduction) for both CD4(+) and CD8(+) Tem, while central memory T cells (Tcm) ( CCR7(+) CD45RA(-)) were less affected, and nave T cells (CCR7(+) CD45RA(+)) were relatively spared. Circulating CD8(+) effector T cells and Type 1 T cells ( IFN-gamma- producing) were also significantly reduced. Conclusion: Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells ( Tcm) in psoriasis.

引用

页数：7

共 23 条

[11] Treatment of psoriasis with alefacept - Correlation of clinical improvement with reductions of memory T-Cell counts [J].

Gordon, KB ;

Vaishnaw, AK ;

O'Gorman, J ;

Haney, J ;

Menter, A .

ARCHIVES OF DERMATOLOGY, 2003, 139 (12) :1563-1570

[12] CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept:: Results of a randomized study [J].

Gottlieb, AB ;

Casale, TB ;

Frankel, E ;

Goffe, B ;

Lowe, N ;

Ochs, HD ;

Roberts, JL ;

Washenik, K ;

Vaishnaw, AK ;

Gordon, KB .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (05) :816-825

[13] The aging of the immune system [J].

Grubeck-Loebenstein, B ;

Wick, G .

ADVANCES IN IMMUNOLOGY, VOL 80, 2002, 80 :243-284

[14] Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients [J].

Haider, Asifa S. ;

Lowes, Michelle A. ;

Gardner, Humphrey ;

Bandaru, Raj ;

Darabi, Kamruz ;

Chamian, Francesca ;

Kikuchi, Toyoko ;

Gilleaudeau, Patricia ;

Whalen, Mary S. ;

Cardinale, Irma ;

Novitskaya, Inna ;

Krueger, James G. .

JOURNAL OF IMMUNOLOGY, 2007, 178 (11) :7442-7449

[15] Phenotypic and functional separation of memory and effector human CD8(+) T cells [J].

Hamann, D ;

Baars, P ;

Rep, MHG ;

Hooibrink, B ;

KerkhofGarde, SR ;

Klein, MR ;

vanLier, RAW .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (09) :1407-1418

[16] The immunologic basis for the treatment of psoriasis with new biologic agents [J].

Krueger, JG .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (01) :1-23

[17] An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2(+) human T cells in vitro [J].

Latinne, D ;

DeLaParra, B ;

Nizet, Y ;

Cornet, A ;

GiovinoBarry, V ;

Monroy, RL ;

WhiteScharf, ME ;

Bazin, H .

INTERNATIONAL IMMUNOLOGY, 1996, 8 (07) :1113-1119

[18] Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'type 1' inflammatory gene expression [J].

Lew, W ;

Bowcock, AM ;

Krueger, JG .

TRENDS IN IMMUNOLOGY, 2004, 25 (06) :295-305

[19]

MAJEAU GR, 1994, J IMMUNOL, V152, P2753

[20] SPECIFIC INTERACTION OF LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-3 WITH CD2 CAN INHIBIT T-CELL RESPONSES [J].

MILLER, GT ;

HOCHMAN, PS ;

MEIER, W ;

TIZARD, R ;

BIXLER, SA ;

ROSA, MD ;

WALLNER, BP .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (01) :211-222

← 1 2 3 →